^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD79B expression

    i
    Other names: CD79B, B-Cell Antigen Receptor Complex-Associated Protein Beta Chain, CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta, IGB, B29, CD79b Antigen (Immunoglobulin-Associated Beta), CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Antigen, AGM6
    Entrez ID:
    974
    Related biomarkers:
    Mutation
    1m
    Systemic deficits in lipid homeostasis promote aging-associated impairments in B cell progenitor development. (PubMed, bioRxiv)
    Together, these findings uncover new roles for lipid metabolism enzymes in the molecular regulation of cellular aging and immune cell function in mouse and human hematopoiesis. In addition, because systemic loss of ELOVL2 enzymatic activity resulted in down-regulation of B cell genes that are also associated with lymphoproliferative neoplasms, this study sheds light on an intriguing metabolic pathway that could be leveraged in future studies as a novel therapeutic modality to target blood cancers or other age-related conditions involving the B cell lineage.
    Journal
    |
    CD79B (CD79b Molecule) • CD34 (CD34 molecule)
    |
    CD79B mutation • CD79B expression
    11ms
    Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Dec 2025 | Initiation date: Dec 2023 --> Sep 2024 | Trial primary completion date: May 2025 --> Dec 2025
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    IFNG (Interferon, gamma) • CD79B (CD79b Molecule) • CD4 (CD4 Molecule)
    |
    CD79B expression
    |
    lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    12ms
    Human CD79b neutrophils in the blood are associated with early-stage melanoma. (PubMed, Front Immunol)
    Compared to remaining blood neutrophils, CD79b neutrophils are primed for NETosis, express higher levels of antigen presentation-related proteins, and have an increased capacity for phagocytosis. Our work suggests that CD79b neutrophils are associated with early-stage melanoma.
    Journal
    |
    CD79B (CD79b Molecule) • CEACAM8 (CEA Cell Adhesion Molecule 8) • SIGLEC8 (Sialic Acid Binding Ig Like Lectin 8)
    |
    CD79B expression
    12ms
    Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. (PubMed, J Immunother Cancer)
    Our results indicated that this novel CD79b CAR T-cell therapy product has robust antitumor activity against B-cell lymphomas. These results supported initiation of a phase 1 clinical trial to evaluate this product in patients with relapsed or refractory B-cell lymphomas.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD79B (CD79b Molecule)
    |
    CD79B expression
    1year
    Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model (ASH 2023)
    Loncastuximab teserine had a deleterious effect on several hematologic parameters, which was not observed with VIP924 or polatuzumab vedotin. The efficacy and tolerability observed in this study with VIP924 suggests further testing in human clinical trials is warranted.
    Preclinical
    |
    CD79B (CD79b Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CD79B expression • CXCR5 expression
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq) • VIP924
    1year
    Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma. (PubMed, Pediatric Health Med Ther)
    The pivotal Phase II study, GO29365, demonstrated that PV in combination with bendamustine and rituximab (BR) significantly improved progression-free survival and overall survival compared to BR alone in patients with relapsed/refractory DLBCL who ineligible for stem cell transplantation were. Overall, PV has emerged as a valuable treatment option for patients with relapsed/refractory DLBCL and HGBCL, offering improved outcomes when combined with appropriate chemotherapy regimens. Ongoing research and clinical trials are further exploring PV's potential in various treatment settings, including frontline therapy and in combination with other novel agents.
    Review • Journal
    |
    CD79B (CD79b Molecule)
    |
    CD79B expression
    |
    Rituxan (rituximab) • bendamustine • Polivy (polatuzumab vedotin-piiq)